{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:53:23Z","timestamp":1788260003454,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12138"],"award-info":[{"award-number":["12138"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preoperative instead of standard postoperative partial breast irradiation (PBI) after breast-conserving surgery (BCS) has the advantage of reducing the irradiated breast volume, toxicity, and number of radiotherapy sessions and can allow tumor downstaging. In this review, we assessed tumor response and clinical outcomes after preoperative PBI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of studies on preoperative PBI in patients with low-risk breast cancer using the databases Ovid Medline, Embase.com, Web of Science (Core Collection), and Scopus (PROSPERO registration CRD42022301435). References of eligible manuscripts were checked for other relevant manuscripts. The primary outcome measure was pathologic complete response (pCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of eight prospective and one retrospective cohort study were identified (\n                      <jats:italic>n<\/jats:italic>\n                      = 359). In up to 42% of the patients, pCR was obtained and this increased after a longer interval between radiotherapy and BCS (0.5\u20138 months). After a maximum median follow-up of 5.0 years, three studies on external beam radiotherapy reported low local recurrence rates (0\u20133%) and overall survival of 97\u2013100%. Acute toxicity consisted mainly of grade 1 skin toxicity (0\u201334%) and seroma (0\u201331%). Late toxicity was predominantly fibrosis grade 1 (46\u2013100%) and grade 2 (10\u201311%). Cosmetic outcome was good to excellent in 78\u2013100% of the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative PBI showed a higher pCR rate after a longer interval between radiotherapy and BCS. Mild late toxicity and good oncological and cosmetic outcomes were reported. In the ongoing ABLATIVE-2 trial, BCS is performed at a longer interval of 12 months after preoperative PBI aiming to achieve a higher pCR rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-023-13233-9","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T14:02:44Z","timestamp":1677852164000},"page":"3263-3279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-2451","authenticated-orcid":false,"given":"Yasmin A.","family":"Civil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysanne W.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje P. M.","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya M.","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene L.","family":"Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"van der Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. G. Desir\u00e9e","family":"van den Bongard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"3","key":"13233_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"13233_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","volume":"367","author":"A Bleyer","year":"2012","unstructured":"Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998\u20132005.","journal-title":"N Engl J Med"},{"issue":"11","key":"13233_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205\u201340.","journal-title":"Br J Cancer"},{"issue":"16","key":"13233_CR4","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233\u201341.","journal-title":"N Engl J Med."},{"issue":"16","key":"13233_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa020989","volume":"347","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227\u201332.","journal-title":"N Engl J Med"},{"issue":"14","key":"13233_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/jnci\/92.14.1143","volume":"92","author":"JA van Dongen","year":"2000","unstructured":"van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"9503","key":"13233_CR7","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087\u2013106.","journal-title":"Lancet"},{"issue":"9804","key":"13233_CR8","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"S Darby","year":"2011","unstructured":"Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707\u201316.","journal-title":"Lancet"},{"issue":"3","key":"13233_CR9","first-page":"161","volume":"8","author":"ER Fisher","year":"1992","unstructured":"Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8(3):161\u20136.","journal-title":"Semin Surg Oncol"},{"issue":"9","key":"13233_CR10","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1245\/s10434-020-09447-w","volume":"28","author":"C Shah","year":"2021","unstructured":"Shah C, Jia X, Hobbs BP, et al. Outcomes with partial breast irradiation vs. whole breast irradiation: a meta-analysis. Ann Surg Oncol. 2021;28(9):4985\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"13233_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.prro.2016.09.007","volume":"7","author":"C Correa","year":"2017","unstructured":"Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73\u20139.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"13233_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.radonc.2010.01.014","volume":"94","author":"C Polgar","year":"2010","unstructured":"Polgar C, Van Limbergen E, Potter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94(3):264\u201373.","journal-title":"Radiother Oncol"},{"issue":"1","key":"13233_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12885-021-08047-5","volume":"21","author":"CN Chu","year":"2021","unstructured":"Chu CN, Hu KC, Wu RS, Bau DT. Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy. BMC Cancer. 2021;21(1):330.","journal-title":"BMC Cancer"},{"issue":"1","key":"13233_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2012.04.025","volume":"104","author":"M Mukesh","year":"2012","unstructured":"Mukesh M, Harris E, Jena R, Evans P, Coles C. Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiother Oncol. 2012;104(1):1\u201310.","journal-title":"Radiother Oncol"},{"issue":"11","key":"13233_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987\u201398.","journal-title":"N Engl J Med"},{"issue":"15","key":"13233_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","volume":"35","author":"C Taylor","year":"2017","unstructured":"Taylor C, Correa C, Duane FK, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641\u20139.","journal-title":"J Clin Oncol"},{"issue":"10099","key":"13233_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","volume":"390","author":"CE Coles","year":"2017","unstructured":"Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048\u201360.","journal-title":"Lancet"},{"issue":"35","key":"13233_CR18","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1200\/JCO.20.00650","volume":"38","author":"I Meattini","year":"2020","unstructured":"Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020;38(35):4175\u201383.","journal-title":"J Clin Oncol"},{"issue":"5","key":"13233_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.ijrobp.2009.01.009","volume":"75","author":"JT Hepel","year":"2009","unstructured":"Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75(5):1290\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"13233_CR20","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.2013.51.1717","volume":"31","author":"R Jagsi","year":"2013","unstructured":"Jagsi R, Haffty BG. External-beam accelerated partial-breast irradiation: exploring the limits of tolerability. J Clin Oncol. 2013;31(32):4029\u201331.","journal-title":"J Clin Oncol"},{"issue":"10215","key":"13233_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","volume":"394","author":"TJ Whelan","year":"2019","unstructured":"Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165\u201372.","journal-title":"Lancet"},{"key":"13233_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01485","author":"B Meduri","year":"2023","unstructured":"Meduri B, Baldissera A, Iotti C, et al. Cosmetic results and side effects of accelerated partial-breast irradiation versus whole-breast irradiation for low-risk invasive carcinoma of the breast: the randomized phase III IRMA trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.22.01485.","journal-title":"J Clin Oncol"},{"issue":"1","key":"13233_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijrobp.2010.09.041","volume":"82","author":"M Palta","year":"2012","unstructured":"Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):37\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13233_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1748-717X-9-63","volume":"9","author":"MD den Hartogh","year":"2014","unstructured":"den Hartogh MD, Philippens ME, van Dam IE, et al. MRI and CT imaging for preoperative target volume delineation in breast-conserving therapy. Radiat Oncol. 2014;9:63.","journal-title":"Radiat Oncol"},{"issue":"1","key":"13233_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijrobp.2009.04.063","volume":"77","author":"EM Nichols","year":"2010","unstructured":"Nichols EM, Dhople AA, Mohiuddin MM, Flannery TW, Yu CX, Regine WF. Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early-stage breast cancer: implications for the future. Int J Radiat Oncol Biol Phys. 2010;77(1):197\u2013202.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"13233_CR26","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.","journal-title":"PLoS Med."},{"key":"13233_CR27","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"13233_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctro.2019.12.004","volume":"21","author":"M Mouawad","year":"2020","unstructured":"Mouawad M, Biernaski H, Brackstone M, et al. DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: comparisons of single versus three fraction schemes and two different imaging time delays post-SABR. Clin Transl Radiat Oncol. 2020;21:25\u201331.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"13233_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.27915","volume":"119","author":"NA Vanderwalde","year":"2013","unstructured":"Vanderwalde NA, Jones EL, Kimple RJ, et al. Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria. Cancer. 2013;119(9):1736\u201343.","journal-title":"Cancer"},{"key":"13233_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jbi\/wbac013","volume":"4","author":"R Jared Weinfurtner","year":"2022","unstructured":"Jared Weinfurtner R, Abdalah MA, Stringfield O, et al. Quantitative changes in intratumoral habitats on MRI correlate with pathologic response in early-stage ER\/PR+ HER2\u2212 breast cancer treated with preoperative stereotactic ablative body radiotherapy. J Breast Imaging. 2022;4:273.","journal-title":"J Breast Imaging"},{"issue":"2","key":"13233_CR31","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/j.clbc.2021.06.016","volume":"22","author":"RJ Weinfurtner","year":"2022","unstructured":"Weinfurtner RJ, Raghunand N, Stringfield O, et al. MRI response to pre-operative stereotactic ablative body radiotherapy (SABR) in early stage ER\/PR+ HER2- breast cancer correlates with surgical pathology tumor bed cellularity. Clin Breast Cancer. 2022;22(2):e214\u201323.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"13233_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijrobp.2019.09.002","volume":"106","author":"SCJ Bosma","year":"2020","unstructured":"Bosma SCJ, Hoogstraat M, van der Leij F, et al. Response to preoperative radiation therapy in relation to gene expression patterns in breast cancer patients. Int J Radiat Oncol Biol Phys. 2020;106(1):174\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"13233_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ijrobp.2019.12.037","volume":"106","author":"SCJ Bosma","year":"2020","unstructured":"Bosma SCJ, Leij F, Vreeswijk S, et al. Five-year results of the preoperative accelerated partial breast irradiation (PAPBI) trial. Int J Radiat Oncol Biol Phys. 2020;106(5):958\u201367.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"13233_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2016.11.030","volume":"97","author":"E Nichols","year":"2017","unstructured":"Nichols E, Kesmodel SB, Bellavance E, et al. Preoperative accelerated partial breast irradiation for early-stage breast cancer: preliminary results of a prospective, phase 2 trial. Int J Radiat Oncol Biol Phys. 2017;97(4):747\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"13233_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3747\/co.26.4479","volume":"26","author":"K Guidolin","year":"2019","unstructured":"Guidolin K, Yaremko B, Lynn K, et al. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the signal prospective single-arm trial of single-dose radiation therapy. Curr Oncol. 2019;26(3):334\u201340.","journal-title":"Curr Oncol"},{"issue":"4","key":"13233_CR36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ijrobp.2015.03.007","volume":"92","author":"JK Horton","year":"2015","unstructured":"Horton JK, Blitzblau RC, Yoo S, et al. Preoperative single-fraction partial breast radiation therapy: a novel phase 1, dose-escalation protocol with radiation response biomarkers. Int J Radiat Oncol Biol Phys. 2015;92(4):846\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"13233_CR37","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/1533034615593191","volume":"15","author":"C Wang","year":"2016","unstructured":"Wang C, Horton JK, Yin FF, Chang Z. Assessment of treatment response with diffusion-weighted MRI and dynamic contrast-enhanced MRI in patients with early-stage breast cancer treated with single-dose preoperative radiotherapy: initial results. Technol Cancer Res Treat. 2016;15(5):651\u201360.","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"13233_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ijrobp.2019.11.406","volume":"106","author":"JE Vasmel","year":"2020","unstructured":"Vasmel JE, Charaghvandi RK, Houweling AC, et al. Tumor response after neoadjuvant magnetic resonance guided single ablative dose partial breast irradiation. Int J Radiat Oncol Biol Phys. 2020;106(4):821\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"13233_CR39","doi-asserted-by":"publisher","first-page":"100854","DOI":"10.1016\/j.adro.2021.100854","volume":"7","author":"JE Vasmel","year":"2022","unstructured":"Vasmel JE, Groot Koerkamp ML, Mandija S, et al. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging for response evaluation after single-dose ablative neoadjuvant partial breast irradiation. Adv Radiat Oncol. 2022;7(2):100854.","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"13233_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijrobp.2009.10.032","volume":"79","author":"RJ Kimple","year":"2011","unstructured":"Kimple RJ, Klauber-DeMore N, Kuzmiak CM, et al. Cosmetic outcomes for accelerated partial breast irradiation before surgical excision of early-stage breast cancer using single-dose intraoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(2):400\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"13233_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3747\/co.27.6059","volume":"27","author":"D Tiberi","year":"2020","unstructured":"Tiberi D, Vavassis P, Nguyen D, et al. Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer. Curr Oncol. 2020;27(3):155\u20138.","journal-title":"Curr Oncol"},{"key":"13233_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ctro.2022.09.004","volume":"37","author":"I Meattini","year":"2022","unstructured":"Meattini I, Francolini G, Di Cataldo V, et al. Preoperative robotic radiosurgery for early breast cancer: results of the phase II ROCK trial (NCT03520894). Clin Transl Radiat Oncol. 2022;37:94\u2013100.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"13233_CR43","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ijrobp.2021.02.033","volume":"110","author":"SCJ Bosma","year":"2021","unstructured":"Bosma SCJ, van der Leij F, Elkhuizen PHM, et al. Evaluation of early response to preoperative accelerated partial breast irradiation (PAPBI) by Histopathology, magnetic resonance imaging, and 18F-fluorodexoyglucose positron emission tomography\/computed tomography (FDG PET\/CT). Int J Radiat Oncol Biol Phys. 2021;110(4):1151\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13233_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3332\/ecancer.2021.1175","volume":"15","author":"M Ahmed","year":"2021","unstructured":"Ahmed M, Jozsa F, Douek M. A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer. Ecancermedicalscience. 2021;15:1175.","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"13233_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/oxfordjournals.annonc.a058929","volume":"5","author":"VF Semiglazov","year":"1994","unstructured":"Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994;5(7):591\u20135.","journal-title":"Ann Oncol"},{"issue":"4","key":"13233_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.1024","volume":"96","author":"E Calitchi","year":"2001","unstructured":"Calitchi E, Kirova YM, Otmezguine Y, Feuilhade F, Piedbois Y, Le Bourgeois JP. Long-term results of neoadjuvant radiation therapy for breast cancer. Int J Cancer. 2001;96(4):253\u20139.","journal-title":"Int J Cancer"},{"key":"13233_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.01.022","volume":"76","author":"FG Riet","year":"2017","unstructured":"Riet FG, Fayard F, Arriagada R, et al. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. Eur J Cancer. 2017;76:45\u201351.","journal-title":"Eur J Cancer"},{"issue":"3","key":"13233_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/rg.2021200134","volume":"41","author":"B Reig","year":"2021","unstructured":"Reig B, Lewin AA, Du L, et al. Breast MRI for evaluation of response to neoadjuvant therapy. Radiographics. 2021;41(3):665\u201379.","journal-title":"Radiographics"},{"issue":"2","key":"13233_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"MB Lobbes","year":"2013","unstructured":"Lobbes MB, Prevos R, Smidt M, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging. 2013;4(2):163\u201375.","journal-title":"Insights Imaging"},{"issue":"3","key":"13233_CR50","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2214\/ajr.184.3.01840868","volume":"184","author":"E Yeh","year":"2005","unstructured":"Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol. 2005;184(3):868\u201377.","journal-title":"Am J Roentgenol"},{"issue":"12","key":"13233_CR51","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1245\/s10434-021-10117-8","volume":"28","author":"FK Palshof","year":"2021","unstructured":"Palshof FK, Lanng C, Kroman N, et al. Prediction of Pathologic complete response in breast cancer patients comparing magnetic resonance imaging with ultrasound in neoadjuvant setting. Ann Surg Oncol. 2021;28(12):7421\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"13233_CR52","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1007\/s00330-022-08667-w","volume":"32","author":"S Du","year":"2022","unstructured":"Du S, Gao S, Zhao R, et al. Contrast-free MRI quantitative parameters for early prediction of pathological response to neoadjuvant chemotherapy in breast cancer. Eur Radiol. 2022;32(8):5759\u201372.","journal-title":"Eur Radiol"},{"key":"13233_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08461-0","author":"J Kim","year":"2022","unstructured":"Kim J, Han BK, Ko EY, Ko ES, Choi JS, Park KW. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes. Eur Radiol. 2022. https:\/\/doi.org\/10.1007\/s00330-021-08461-0.","journal-title":"Eur Radiol"},{"issue":"1","key":"13233_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tranon.2015.11.016","volume":"9","author":"A Tudorica","year":"2016","unstructured":"Tudorica A, Oh KY, Chui SY, et al. Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI. Transl Oncol. 2016;9(1):8\u201317.","journal-title":"Transl Oncol"},{"issue":"5","key":"13233_CR55","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s00330-015-3948-0","volume":"26","author":"S Drisis","year":"2016","unstructured":"Drisis S, Metens T, Ignatiadis M, Stathopoulos K, Chao SL, Lemort M. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. Eur Radiol. 2016;26(5):1474\u201384.","journal-title":"Eur Radiol"},{"issue":"1","key":"13233_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-021-01489-6","volume":"23","author":"J Virostko","year":"2021","unstructured":"Virostko J, Sorace AG, Slavkova KP, et al. Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting. Breast Cancer Res. 2021;23(1):110.","journal-title":"Breast Cancer Res"},{"issue":"9381","key":"13233_CR57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","volume":"362","author":"JC Chang","year":"2003","unstructured":"Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362(9381):362\u20139.","journal-title":"Lancet."},{"issue":"21","key":"13233_CR58","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.3390\/cancers13215477","volume":"13","author":"AJA Freitas","year":"2021","unstructured":"Freitas AJA, Causin RL, Varuzza MB, et al. Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review. Cancers. 2021;13(21):5477.","journal-title":"Cancers"},{"issue":"51","key":"13233_CR59","doi-asserted-by":"publisher","first-page":"e9384","DOI":"10.1097\/MD.0000000000009384","volume":"96","author":"M Tao","year":"2017","unstructured":"Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine. 2017;96(51):e9384.","journal-title":"Medicine"},{"issue":"9","key":"13233_CR60","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/fon-2016-0420","volume":"13","author":"X Chen","year":"2017","unstructured":"Chen X, He C, Han D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(9):843\u201357.","journal-title":"Future Oncol"},{"key":"13233_CR61","doi-asserted-by":"publisher","first-page":"151930","DOI":"10.1016\/j.anndiagpath.2022.151930","volume":"58","author":"O Okcu","year":"2022","unstructured":"Okcu O, Ozturk SD, Ozturk C, Sen B, Yasin AI, Bedir R. Tumor-infiltrating lymphocytes (TILs)\/volume and prognosis: the value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy. Ann Diagn Pathol. 2022;58:151930.","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"13233_CR62","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-017-4191-y","volume":"163","author":"MV Dieci","year":"2017","unstructured":"Dieci MV, Frassoldati A, Generali D, et al. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+\/HER2- breast cancer: results from two prospective trials. Breast Cancer Res Treat. 2017;163(2):295\u2013302.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"13233_CR63","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ijrobp.2020.12.009","volume":"109","author":"JE Vasmel","year":"2021","unstructured":"Vasmel JE, Vreuls CPH, Manson QF, et al. Tumor-infiltrating lymphocytes in low-risk patients with breast cancer treated with single-dose preoperative partial breast irradiation. Int J Radiat Oncol Biol Phys. 2021;109(5):1325\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10215","key":"13233_CR64","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","volume":"394","author":"FA Vicini","year":"2019","unstructured":"Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155\u201364.","journal-title":"Lancet"},{"issue":"1","key":"13233_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13058-017-0870-1","volume":"19","author":"J Poleszczuk","year":"2017","unstructured":"Poleszczuk J, Luddy K, Chen L, et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017;19(1):75.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"13233_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.semradonc.2013.05.009","volume":"23","author":"B Burnette","year":"2013","unstructured":"Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol. 2013;23(4):273\u201380.","journal-title":"Semin Radiat Oncol"},{"key":"13233_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.11.008","author":"MCT Batenburg","year":"2022","unstructured":"Batenburg MCT, van der Molen MDR, van der Leij F, et al. Patient-reported symptoms of late toxicity in patients with breast cancer treated with hypofractionated radiation therapy and the association with quality of life. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.11.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"13233_CR68","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ijrobp.2010.01.059","volume":"77","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Yarnold JR. Reports of unexpected late side effects of accelerated partial breast irradiation\u2014radiobiological considerations. Int J Radiat Oncol Biol Phys. 2010;77(4):969\u201373.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"13233_CR69","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ijrobp.2020.11.044","volume":"109","author":"RR Boutrus","year":"2021","unstructured":"Boutrus RR, El Sherif S, Abdelazim Y, et al. Once daily versus twice daily external beam accelerated partial breast irradiation: a randomized prospective study. Int J Radiat Oncol Biol Phys. 2021;109(5):1296\u2013300.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13233_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.radonc.2022.09.024","volume":"177","author":"MS Thomsen","year":"2022","unstructured":"Thomsen MS, Alsner J, Nielsen HM, et al. Volume matters: breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial. Radiother Oncol. 2022;177:231\u20135.","journal-title":"Radiother Oncol"},{"issue":"1","key":"13233_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijrobp.2009.01.041","volume":"76","author":"R Jagsi","year":"2010","unstructured":"Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(1):71\u20138.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"13233_CR72","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/bjs.4344","volume":"90","author":"RA Cochrane","year":"2003","unstructured":"Cochrane RA, Valasiadou P, Wilson AR, Al-Ghazal SK, Macmillan RD. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003;90(12):1505\u20139.","journal-title":"Br J Surg"},{"issue":"3","key":"13233_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","volume":"114","author":"RN Pedersen","year":"2022","unstructured":"Pedersen RN, Esen BO, Mellemkjaer L, et al. The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis. J Natl Cancer Inst. 2022;114(3):391\u20139.","journal-title":"J Natl Cancer Inst."},{"issue":"10237","key":"13233_CR74","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613\u201326.","journal-title":"Lancet"},{"issue":"11","key":"13233_CR75","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086\u201394.","journal-title":"Lancet Oncol"},{"issue":"6","key":"13233_CR76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513\u201320.","journal-title":"N Engl J Med."},{"issue":"3","key":"13233_CR77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.breast.2010.03.003","volume":"19","author":"Y Lievens","year":"2010","unstructured":"Lievens Y. Hypofractionated breast radiotherapy: financial and economic consequences. Breast. 2010;19(3):192\u20137.","journal-title":"Breast"},{"issue":"1","key":"13233_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.brachy.2019.10.007","volume":"19","author":"J-M Hannoun-L\u00e9vi","year":"2020","unstructured":"Hannoun-L\u00e9vi J-M, Lam-Cham-Kee D, Gal J, et al. Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation (SiFEBI) phase I\/II trial. Brachytherapy. 2020;19(1):90\u20136.","journal-title":"Brachytherapy"},{"issue":"1","key":"13233_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2018.12.050","volume":"104","author":"AJ Khan","year":"2019","unstructured":"Khan AJ, Chen PY, Yashar C, et al. Three-fraction accelerated partial breast irradiation (APBI) delivered with brachytherapy applicators is feasible and safe: first results from the TRIUMPH-T trial. Int J Radiat Oncol Biol Phys. 2019;104(1):67\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"13233_CR80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13014-019-1417-7","volume":"14","author":"RW Mutter","year":"2019","unstructured":"Mutter RW, Jethwa KR, Gonuguntla K, et al. 3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. Radiat Oncol. 2019;14(1):211.","journal-title":"Radiat Oncol"},{"issue":"2","key":"13233_CR81","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2020.02.021","volume":"107","author":"WR Kennedy","year":"2020","unstructured":"Kennedy WR, Thomas MA, Stanley JA, et al. Single-institution phase 1\/2 prospective clinical trial of single-fraction, high-gradient adjuvant partial-breast irradiation for hormone sensitive stage 0\u2013i breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(2):344\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"13233_CR82","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.radonc.2013.10.033","volume":"110","author":"F van der Leij","year":"2014","unstructured":"van der Leij F, Elkhuizen PHM, Janssen TM, et al. Target volume delineation in external beam partial breast irradiation: less inter-observer variation with preoperative- compared to postoperative delineation. Radiother Oncol. 2014;110(3):467\u201370.","journal-title":"Radiother Oncol"},{"issue":"3","key":"13233_CR83","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","volume":"16","author":"IH Kunkler","year":"2015","unstructured":"Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266\u201373.","journal-title":"Lancet Oncol"},{"issue":"19","key":"13233_CR84","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","volume":"31","author":"KS Hughes","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382\u20137.","journal-title":"J Clin Oncol."},{"issue":"17_suppl","key":"13233_CR85","doi-asserted-by":"publisher","first-page":"LBA501","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA501","volume":"40","author":"TJ Whelan","year":"2022","unstructured":"Whelan TJ, Smith S, Nielsen TO, et al. LUMINA: a prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol. 2022;40(17_suppl):LBA501\u2013LBA501.","journal-title":"J Clin Oncol"},{"issue":"11","key":"13233_CR86","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.ejca.2015.04.018","volume":"51","author":"G Martelli","year":"2015","unstructured":"Martelli G, Boracchi P, Guzzetti E, et al. Omission of radiotherapy in elderly patients with early breast cancer: 15-year results of a prospective non-randomised trial. Eur J Cancer. 2015;51(11):1358\u201364.","journal-title":"Eur J Cancer"},{"key":"13233_CR87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Mohd Tahir NA, Hatah E, Mohamed SN. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast. 2022;62:22\u201335.","journal-title":"Breast"},{"issue":"11","key":"13233_CR88","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","volume":"30","author":"AR Ferreira","year":"2019","unstructured":"Ferreira AR, Di Meglio A, Pistilli B, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol. 2019;30(11):1784\u201395.","journal-title":"Ann Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13233-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T19:07:50Z","timestamp":1683832070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13233-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["13233"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13233-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}